secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2026-09-11T12:00:26+00:00
Accession:  0001193125-26-388631
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

TScan Therapeutics approves retention program with cash and RSUs for CEO and Chief Legal Officer
--------------------------------------------------------------------------------

- CEO Gavin MacBeath receives $822,000 cash award and 2,400,000 RSUs under Retention Program.
- CLSO Zoran Zdraveski receives $416,000 cash award and 1,050,000 RSUs under Retention Program.
- Cash awards: first half paid Nov 2026 and Feb 2027; second half on in vivo solid tumor clinical milestone.
- RSUs: one-third vest on financing milestone; remaining two-thirds over first two anniversaries of that milestone.
- Program aims to retain key employees supporting company, granted under 2021 Equity Incentive Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312526388631/0001193125-26-388631-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312526388631/d171735d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-388631

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer